Danaher Corporation

NYSE DHR

Data sourced from

and

Download Data

Danaher Corporation Interest Expense To Sales 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: 53.65%

Danaher Corporation Interest Expense To Sales 1 year YoY Change (%) is 53.65% for the Trailing 12 Months (TTM) ending March 31, 2024, a 992.52% change year over year. The interest expense to sales ratio is a financial metric that represents the proportion of a company's revenue that is used to cover its interest expenses. It is calculated by dividing the company's interest expense by its total revenue. This ratio indicates the financial burden of interest payments on the company's operating income. A higher ratio suggests that a significant portion of the company's revenue is being used to service interest obligations, potentially affecting its profitability. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Danaher Corporation Interest Expense To Sales for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.73%, a -6.01% change year over year.
Danaher Corporation Interest Expense To Sales for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.78%, a -33.88% change year over year.
Danaher Corporation Interest Expense To Sales for the Trailing 12 Months (TTM) ending March 31, 2021 was 1.17%, a 60.63% change year over year.
Danaher Corporation Interest Expense To Sales for the Trailing 12 Months (TTM) ending March 31, 2020 was 0.73%, a 3.50% change year over year.

NYSE: DHR

Danaher Corporation

CEO	Mr. Steven M. Rales
IPO Date	Jan. 5, 1979
Location	United States
Headquarters	2200 Pennsylvania Avenue, NW, Washington, DC, United States, 20037-1701
Employees	61,000
Sector	Healthcare
Industry	Diagnostics & research

Description

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Key trends